Protective efficacy of a bivalent inactivated reassortant H1N1 influenza virus vaccine against European avian-like and classical swine influenza H1N1 viruses in mice
Protective efficacy of a bivalent inactivated reassortant H1N1 influenza virus vaccine against European avian-like and classical swine influenza H1N1 viruses in mice
复制标题
DOI：
10.1016/j.vetmic.2020.108724
复制
发表时间：
2020-07-01
影响因子：
3.3
通讯作者：
Tong, Guang-Zhi
中科院分区：
文献类型：
--
作者：
Ruan, Bao-Yang;Yao, Yun;Tong, Guang-Zhi
2009年，经典猪（CS）H1N1猪流感病毒（SIV）在人类中出现，作为引起H1N1流感病毒大流行的一种可供参考的病毒，而欧洲禽样（EA）H1N1 SIV已在欧洲和亚洲国家引起数起人类感染。开发能够对SIV提供有效保护效力的流感疫苗仍然是一个挑战。本研究以H1N1亚型SIV流行株CS和EA的血凝素（HA）和神经氨酸酶（NA）基因和A/波多黎各/8/34（PR 8）的6个内源基因为基础，构建了SH 1/PR 8和G11/PR 8双价灭活疫苗。在用致死剂量的CS和EA H1N1 SIV攻击的小鼠中评价该二价疫苗的保护效力。结果表明，单价灭活疫苗可诱导高水平的抗同源H1N1病毒抗体，而对异源H1N1病毒的交叉反应性抗体应答并不完全有效。在小鼠模型中，二价灭活疫苗对致死攻击剂量的EA SH 1病毒或CS G11病毒具有完全保护作用，而单价灭活疫苗仅对异源SIV产生不充分的保护作用。总之，我们的数据表明，由SH 1/PR 8和G11/PR 8组成的重配双价灭活疫苗可以对小鼠中流行的EA和CS H1N1亚型SIV提供有效的保护。
The classical swine (CS) H1N1 swine influenza virus (SIVs) emerged in humans as a reassortant virus that caused the H1N1 influenza virus pandemic in 2009, and the European avian-like (EA) H1N1 SIVs has caused several human infections in European and Asian countries. Development of the influenza vaccines that could provide effective protective efficacy against SIVs remains a challenge. In this study, the bivalent reassortant inactivated vaccine comprised of SH1/PR8 and G11/PR8 arboring the hemagglutinin (HA) and neuraminidase (NA) genes from prevalent CS and EA H1N1 SIVs and six internal genes from the A/Puerto Rico/8/34(PR8) virus was developed. The protective efficacy of this bivalent vaccine was evaluated in mice challenged with the lethal doses of CS and EA H1N1 SIVs. The result showed that univalent inactivated vaccine elicited high-level antibody against homologous H1N1 viruses while cross-reactive antibody responses to heterologous H1N1 viruses were not fully effective. In a mouse model, the bivalent inactivated vaccine conferred complete protection against lethal challenge doses of EA SH1 virus or CS G11 virus, whereas the univalent inactivated vaccine only produced insufficient protection against heterologous SIVs. In conclusion, our data demonstrated that the reassortant bivalent inactivated vaccine comprised of SH1/PR8 and G11/PR8 could provide effective protection against the prevalent EA and CS H1N1 subtype SIVs in mice.